Pancreatic Polypeptide and Glucose Metabolism

Seymour, Neal E.; Andersen, Dana K.

doi:10.1007/978-1-59259-695-9_13

Cited by 4 publications

(5 citation statements)

References 39 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…One of the elucidated functions of PP is its hypoglycemic activity mediated through reduction in glucose release from liver. Exogenous administration of PP has been shown to increase insulin binding sites in the liver which was later established to be due to significant increase in the gene transcription of beta subunit of insulin receptors (10). This suggests that PP can be used in the modulation and treatment of metabolic disorders such as diabetes and obesity.…”

Section: Discussionmentioning

confidence: 99%

“…The peptide sensitizes the liver to the action of insulin by increasing the number of insulin receptors in the hepatocytes (10–12). PP has also been reported to decrease the expression of resistin hormone that plays a major role in the development of hepatic insulin resistance and elevated levels of resistin is reported in CP (13–15).…”

Section: Introductionmentioning

confidence: 99%

“…PP has also been reported to decrease the expression of resistin hormone that plays a major role in the development of hepatic insulin resistance and elevated levels of resistin is reported in CP (13–15). Needless to say, deficiency of the peptide results in significant hepatic insulin resistance (10,16) as well as glucose intolerance which can be attributed to the impairment of hepatic sensitivity to insulin and up regulation of resistin hormone. In patients with diabetes secondary to CP, administration of PP reverses insulin resistance and improves glucose metabolism (17–19).…”

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Human Pancreatic Polypeptide in a Phospholipid-Based Micellar Formulation

Banerjee

Önyüksel

2012

Pharm Res

View full text Add to dashboard Cite

Purpose Pancreatic polypeptide (PP) has important glucoregulatory functions and thereby holds significance in the treatment of diabetes and obesity. However, short plasma half-life and aggregation propensity of PP in aqueous solution, limits its therapeutic application. To address these issues, we prepared and characterized a formulation of PP in sterically stabilized micelles (SSM) that protects and stabilizes PP in its active conformation. Methods PP-SSM was prepared by incubating PP with SSM dispersion in buffer. Peptide-micelle association and freeze-drying efficacy of the formulation was characterized in phosphate buffers with or without sodium chloride using dynamic light scattering, fluorescence spectroscopy and circular dichroism. The degradation kinetics of PP-SSM in presence of proteolytic enzyme was determined using HPLC and bioactivity of the formulation was evaluated by in vitro cAMP inhibition. Results PP self-associated with SSM and this interaction was influenced by presence/absence of sodium chloride in the buffer. The formulation was effectively lyophilized, demonstrating feasibility for its long-term storage. The stability of peptide against proteolytic degradation was significantly improved and PP in SSM retained its bioactivity in vitro. Conclusions Self-association of PP with phospholipid micelles addressed the delivery issues of the peptide. This PP nanomedicine should be further developed for the treatment of diabetes.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Human Pancreatic Polypeptide in a Phospholipid-Based Micellar Formulation

Banerjee

Önyüksel

2012

Pharm Res

View full text Add to dashboard Cite

show abstract

“…Exogenous administration of ghrelin has been shown to influence food intake, growth, adiposity, insulin secretion, and gastrointestinal function as well as GH secretion (1, 6, I0, 21,22). In humans, ghrelin can also increase blood levels of somatostatin and pancreatic polypeptide, two peptides with metabolic actions (23,24). The stomach-ghrelinpituitary-GH axis links nutritional intake to regulation of GH secretion, growth, and metabolism and would be the first such demonstration of a gastrointestinal-pituitary axis.…”

Section: Discussionmentioning

confidence: 99%

Evidence That Growth Hormone Exerts a Feedback Effect on Stomach Ghrelin Production and Secretion

Xiang

Reed

Englander

et al. 2003

Exp Biol Med (Maywood)

View full text Add to dashboard Cite

Ghrelin is a recently discovered stomach hormone that stimulates pituitary growth hormone (GH) secretion potently. The purpose of these experiments was to test the hypothesis that a stomach-ghrelin-pituitary-GH axis exists in which either an elevation or reduction in systemic GH levels will exert a negative or positive feedback action, respectively, on stomach ghrelin homeostasis. In rats, GH administration decreased stomach ghrelin mRNA levels and plasma ghrelin levels significantly. In GH-releasing hormone (GHRH) transgenic mice, GHRH overexpression decreased stomach ghrelin peptide levels when compared with control mice. In aged rats (25 months) stomach ghrelin mRNA and peptide levels and plasma ghrelin levels were decreased when compared with young rats (5 months). Because GH secretion is reduced in aged rats, the elevated stomach ghrelin production and secretion may reflect a decreased GH feedback on stomach ghrelin, homeostasis, and secretion. Together, these findings suggest that endogenous pituitary GH exerts a feedback action on stomach ghrelin homeostasis and support the hypothesis that a stomach-ghrelin-pituitary GH axis exists.

show abstract

“…Pancreatic polypeptide (PP) is a 42-amino-acid polypeptide localized to specific cells in pancreatic islets [6]. These cells, called PP cells, are located mainly in the ventral pancreatic head and uncinate process.…”

Section: Glucoregulatory Properties Of Pancreatic Polypeptidementioning

confidence: 99%

Pancreatic Resection: Effects on Glucose Metabolism

2001

Self Cite

View full text Add to dashboard Cite

Pancreatic resection results in hormonal abnormalities that are dependent on the extent and location (proximal versus distal) of the resected portion of the gland. The form of glucose intolerance which results from pancreatic resection is termed pancreatogenic diabetes. It is associated with features distinct from both type I (insulin-dependent) and type II (insulin-independent, or adult-onset) diabetes. Hepatic insulin resistance with persistent endogenous glucose production and enhanced peripheral insulin sensitivity result in a brittle form of diabetes which can be difficult to manage. In addition to insulin deficiency, the endocrine abnormalities that accompany pancreatic resection can include glucagon deficiency or pancreatic polypeptide (PP) deficiency if the resection is distal or proximal, respectively. Glucagon deficiency can contribute to iatrogenic hypoglycemia, and PP deficiency can contribute to persistent hyperglycemia due to impaired hepatic insulin action. Pancreatic resections that spare the duodenum, such as distal pancreatectomy, duodenum-preserving pancreatic head resection (Beger procedure), or extended lateral pancreaticojejunostomy with excavation of the pancreatic head (Frey procedure), are associated with a lower incidence of new or worsened diabetes than the standard or pylorus-preserving pancreaticoduodenectomy (Whipple procedure) or total pancreatectomy. Operative considerations for the treatment of pancreatic disease should include strategies to minimize the hormonal impairment of pancreatic resection.

show abstract

Pancreatic Polypeptide and Glucose Metabolism

Cited by 4 publications

References 39 publications

Human Pancreatic Polypeptide in a Phospholipid-Based Micellar Formulation

Human Pancreatic Polypeptide in a Phospholipid-Based Micellar Formulation

Evidence That Growth Hormone Exerts a Feedback Effect on Stomach Ghrelin Production and Secretion

Pancreatic Resection: Effects on Glucose Metabolism

Contact Info

Product

Resources

About